<DOC>
	<DOCNO>NCT01848106</DOCNO>
	<brief_summary>This study design determine efficacy REG1 compare bivalirudin prevent periprocedural ischemic complication major bleed patient undergo PCI treatment CAD . Bivalirudin study patient undergo PCI ACS ( NSTEMI unstable angina [ UA ] ) elective PCI . In comparison UFH , bivalirudin show similar rate ischemic event demonstrate significant reduction bleed improved net clinical benefit . Evidence previous study indicate pegnivacogin represent extremely potent , chemically unique anticoagulant reverse anivamersen across multiple population ( refer Section 1.2.2 ) . The question still remain whether Factor IX ( FIX ) inhibition pegnivacogin result few ischemic event previously study agent active control anivamersen preserve benefit reduce bleeding . The purpose study evaluate REG1 adequately power definitive study open-label , multi-center , active-controlled , randomized design answer question .</brief_summary>
	<brief_title>A Study To Determine Efficacy Safety REG1 Compared Bivalirudin Patients Undergoing PCI</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Bivalirudin</mesh_term>
	<mesh_term>Hirudins</mesh_term>
	<criteria>1 . The study population consist patient CAD undergo PCI . Three key subgroup include 2 . Willing able sign Institutional Review Board/Ethics Committee ( IRB/EC ) approve informed consent prior studyrelated activity ; 3 . Male female age 18 great ; 4 . If female childbearing potential , must negative urine serum pregnancy test postmenopausal least 1 year prior randomization . Females childbearing potential must practice adequate birth control eligible . It Investigator 's responsibility determine whether patient adequate birth control study participation ; 5 . Subject able willing comply protocol study procedures 1 . Acute STsegment elevation myocardial infarction within 48 hour randomization ; 2 . Evidence current clinical instability 3 . Evidence contraindication anticoagulation increase risk bleed 4 . Use investigational drug device within 30 day randomization plan use investigational drug device EOS ( Day 30 followup ) ; 5 . Use select antithrombotic agent 6 . Baseline hemoglobin ( Hgb ) &lt; 9 g/dL equivalent ; 7 . Baseline estimate glomerular filtration rate ( GFR ) ≤ 10 mL/min/1.73m² currently undergo renal replacement therapy ( hemodialysis peritoneal dialysis ) ; 8 . Baseline platelet count &lt; 100,000/mm3 ; 9 . Known allergy intolerance aspirin , available ADP/P2Y12 inhibitor ( clopidogrel , prasugrel , ticagrelor ) , bivalirudin REG1 ( respective component ) ; 10 . The following planned procedure : . Planned stag PCI procedure within 3 day randomization ; b . Planned CABG valve surgery within 30 day randomization ; 11 . Any medical psychiatric condition Investigator 's judgment preclude participation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Percutaneous Coronary Intervention</keyword>
	<keyword>Coronary Artery Disease</keyword>
	<keyword>Acute Coronary Syndrome</keyword>
	<keyword>Regado</keyword>
	<keyword>Reg 1</keyword>
	<keyword>bivalirudin</keyword>
</DOC>